To assess the effect of ridaforolimus on the QTc interval in patients with advanced cancer.
Danielle Sullivan(AbbVie (United States)), A. W. Tolcher(GTx (United States)), Kyriakos P. Papadopoulos(Texas Oncology), Nisha Agrawal, Michele Trucksis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jacqueline B. McCrea(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark Stroh(CytomX Therapeutics (United States)), Amita Patnaik(South Texas Accelerated Research Therapeutics), X. Li, J. A. Wagner, Keith Orford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Iwamoto, K. Cerchio(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k